PS
DNLI icon

Principal Securities’s Denali Therapeutics DNLI Stock Holding History

Principal Securities’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14
Closed -$285 – 3740
2025
Q1 		$285 Hold
14
– – ﹤0.01% 3427
2024
Q4 		$285 Sell
14
-9
-39% -$230 ﹤0.01% 3422
2024
Q3 		$670 Sell
23
-122
-84% -$3.02K ﹤0.01% 3222
2024
Q2 		$3.37K Sell
145
-586
-80% -$11.3K ﹤0.01% 2771
2024
Q1 		$15K Sell
731
-75
-9% -$1.41K ﹤0.01% 2149
2023
Q4 		$17.3K Buy
+806
New +$16K ﹤0.01% 1998

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Securities's DNLI Position: Q2 2025 in Review

Principal Securities sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 14 shares — an estimated $285 sold.

Principal Securities first reported a position in DNLI in Q4 2023 and held it in 6 quarters. The position peaked at $17.3K in Q4 2023. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Principal Securities reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 14 Denali Therapeutics shares in Q2 2025, an estimated $285.
  • Principal Securities first reported a position in Denali Therapeutics in Q4 2023 and held it in 6 quarters.
  • Principal Securities's Denali Therapeutics position peaked at $17.3K in Q4 2023.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.